Cardiometabolic and Lipids Strategies for Endocrinologists-Disease State Network Year-in-Review-Lipids and CV Health

Video Transcription

Video Summary

The video transcript is from a lipidology conference where multiple speakers discuss various topics related to lipid disease and cardiovascular health. The first speaker, Dr. Priya Pulipati, discusses a meta-analysis on statin intolerance, finding that the prevalence of statin intolerance is about 9% in patients. The second speaker, Dr. Elliot Brinton, discusses the use of intermittent fasting and its effects on cardiometabolic risk factors and gut microbiota. He also talks about the efficacy of evanacumab, a monoclonal antibody for the treatment of homozygous familial hypercholesterolemia. The third speaker, Dr. Michael Blaha, discusses the results of the Reduce-It trial, which showed that icosapent ethyl, a pure EPA, can significantly reduce cardiovascular events in patients with high triglycerides and established cardiovascular disease or diabetes. He also mentions the negative results of the Strength trial, which used a mix of EPA and DHA, and the futility findings of the Prominent trial, which tested a fibrate in patients with high triglycerides and low HDL. Overall, the speakers provide updates on the management of lipid diseases and highlight the potential benefits and limitations of various treatments.

Keywords

lipidology conference

statin intolerance

intermittent fasting

evanacumab

homozygous familial hypercholesterolemia

Reduce-It trial

icosapent ethyl

cardiovascular events

EPA and DHA

lipid diseases